These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 16553503)

  • 1. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
    Vo QA; Lin JK; Tong LM
    Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
    Bain J; Meyer A
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S104-9. PubMed ID: 26272889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
    Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
    Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.
    Curzio KM; Cheng-Lai A; Kheyfets V; Sinnet M; Billett HH
    J Thromb Thrombolysis; 2009 Aug; 28(2):117-23. PubMed ID: 18827975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a standardized protocol using lepirudin or argatroban for heparin-induced thrombocytopenia.
    Kennedy K; Steinke D; King S; Poe K; Reeves J; Short M
    Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):262-8. PubMed ID: 21902659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis.
    Sun Z; Lan X; Li S; Zhao H; Tang Z; Xi Y
    Int J Hematol; 2017 Oct; 106(4):476-483. PubMed ID: 28600720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.
    Kiser TH; Fish DN
    Pharmacotherapy; 2006 Apr; 26(4):452-60. PubMed ID: 16553502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.
    Kiser TH; Burch JC; Klem PM; Hassell KL
    Pharmacotherapy; 2008 Sep; 28(9):1115-24. PubMed ID: 18752382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: comparison of clinical outcomes.
    Abel EE; Kane-Gill SL; Seybert AL; Kellum JA
    Am J Health Syst Pharm; 2012 Sep; 69(18):1559-67. PubMed ID: 22935938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.
    Boyce SW; Bandyk DF; Bartholomew JR; Frame JN; Rice L
    Am J Ther; 2011 Jan; 18(1):14-22. PubMed ID: 21079512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia.
    Nikolsky E; Dangas GD
    Semin Thromb Hemost; 2004 Jun; 30(3):305-14. PubMed ID: 15282653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
    Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E
    J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin?
    Seybert AL; Coons JC; Zerumsky K
    Pharmacotherapy; 2006 Feb; 26(2):229-41. PubMed ID: 16466327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.
    Treschan TA; Schaefer MS; Geib J; Bahlmann A; Brezina T; Werner P; Golla E; Greinacher A; Pannen B; Kindgen-Milles D; Kienbaum P; Beiderlinden M
    Crit Care; 2014 Oct; 18(5):588. PubMed ID: 25344113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
    Bartholomew JR; Pietrangeli CE; Hursting MJ
    Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
    John TE; Hallisey RK
    Pharmacotherapy; 2005 Oct; 25(10):1383-8. PubMed ID: 16185183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
    Levine RL; Hursting MJ; McCollum D
    Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for heparin-induced thrombocytopenia.
    Greinacher A
    Am J Health Syst Pharm; 2003 Oct; 60 Suppl 5():S12-8. PubMed ID: 14593978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.